**BACKGROUND:** Autologous fat grafting is a powerful technique for replacing soft tissue but is limited by unpredictable long-term tissue retention and considerable interpatient variability. After injection, fat grafts typically experience extreme ischemia causing adipocytes to necrotize and release factors inducing macrophage recruitment and inflammation. This process continues until tissue revascularization occurs. We hypothesize that reducing tissue inflammation and the rate of necrotic tissue clearance will increase graft retention during the revascularization period, ultimately improving tissue replacement by stem and progenitor cell remodeling. Calcitriol, the active form of vitamin D3, significantly inhibits apoptosis through reduction of oxidative stress and is a potential key stimulator of triglyceride accumulation. This study investigates the novel use of calcitriol for improving adipose tissue survival by reducing inflammation and phagocytic tissue clearance.

**METHODS:** In vitro, adipose tissue from 3 human donors was cultured for 48 hours in 1% oxygen and 0, 15.6, 62.5, and 250 nM calcitriol. Tissue viability was assessed, and quantitative reverse transcriptase polymerase chain reaction was performed to measure genes related to hypoxia or inflammation. In vivo, an immunocompromised mouse model was used to evaluate the impact of calcitriol on fat graft outcomes. Lipoaspirate tissue (0.3 ml) from 3 human donors was implanted bilaterally on the mouse dorsum and assessed at multiple time points out to 12 weeks. Study groups included lipoaspirate incubated with calcitriol for 60 minutes before injection or thrice weekly intraperitoneal calcitriol injections. Study outcomes included residual graft volume (%) and graft injury as observed through histology.

**RESULTS:** Under hypoxic culture conditions, calcitriol did not significantly impact adipocyte viability in vitro but did decrease expression of inflammatory cytokines including SOD1, IFNγ, and interleukin-6. In vivo, lipoaspirate submersion before grafting increased graft retention at 1 week (*P* = 0.081, not statistically significant) and 4 weeks (*P* \< 0.05), whereas intraperitoneal calcitriol injections significantly increased fat graft volume retention at both 1 and 4 weeks (*P* \< 0.01). Results from 12-week data are pending.

**CONCLUSION:** Calcitriol, an Food and Drug Administration--approved drug with known immunomodulatory properties, seems to be a promising drug for improving long-term fat grafting outcomes. In vitro, calcitriol exhibited anti-inflammatory properties and hypoxic tissue had decreased expression of inflammatory cytokines SOD1, IFNγ, and interleukin-6. In vivo, calcitriol submersion and intraperitoneal injection both significantly increased fat graft volume retention by 4 weeks. Used in tumescent fluid, calcitriol has potential as a simple, economical means of increasing fat graft retention.
